TNOX Tanox (MM)

HOUSTON, Aug. 15 /PRNewswire-FirstCall/ -- Tanox, Inc. (NASDAQ:TNOX) has named Linda Paradiso, D.V.M., M.B.A., Vice President of Clinical Operations and Regulatory Affairs. Dr. Paradiso brings 24 years of pharmaceutical and biotechnology industry experience to Tanox in this newly created position to provide leadership for the company's clinical development and regulatory affairs departments. She will report to Tanox President and CEO Nancy Chang. Dr. Paradiso has extensive experience in all facets of drug development and has been involved in developing therapies in the areas of infectious disease, cancer, hematology, pain, and respiratory and pulmonary diseases. She has contributed directly to the worldwide development and lifecycle management of Viracept(R), Penetrex(R), Omnicef(R), Doxil(R), DepoCyt(R), Kepivance(TM), Neulasta(TM) and Aranesp(R). Prior to joining Tanox, Dr. Paradiso was Senior Director, Therapy Area Head for Oncology Regulatory Affairs at Amgen, Inc. in Thousand Oaks, Calif. In this role, she was responsible for global regulatory strategy and program execution for all pre-marketed and marketed oncology products. "Dr. Paradiso's broad experience at both large pharmaceutical companies and emerging biotechs will be a tremendous asset to Tanox," said Chang. "Her expertise in the management of clinical development programs in a wide range of indications and demonstrated leadership capabilities will be extremely valuable as we continue to move our products toward commercialization." In addition to her position at Amgen, Dr. Paradiso previously held senior clinical and regulatory affairs positions at Salmedix, Inc., Pfizer, Inc., Agouron Pharmaceuticals, Inc., and DepoTech Corporation. She began her pharmaceutical career at Warner Lambert (Parke-Davis), where she spent 11 years in clinical and research positions of increasing responsibility. Dr. Paradiso earned her Doctor of Veterinary Medicine degree from Michigan State University and a Master of Business Administration degree from the University of California-Irvine. About Tanox, Inc. Tanox is a biotechnology company specializing in the discovery and development of biotherapeutics based on monoclonal antibody technology. The company develops innovative therapeutic agents for the treatment of immune- mediated diseases, infectious disease, inflammation and cancer. Tanox's lead investigational therapy, TNX-355, is a humanized, anti-CD4 monoclonal antibody to treat HIV and AIDS. TNX-355 received Fast Track Status from the U.S. Food and Drug Administration in 2003 and is currently in Phase 2 clinical testing. Tanox's first-approved drug, Xolair(R) (omalizumab), is the first anti- immunoglobulin E (anti-IgE) antibody to be brought to market. Xolair was developed in collaboration with Genentech, Inc. and Novartis Pharma AG and was approved for marketing in the United States in 2003 for adult and adolescent patients with moderate-to-severe, confirmed allergic asthma. Tanox is based in Houston, Texas and maintains a manufacturing facility in San Diego, California. Additional corporate information is available at http://www.tanox.com/ . http://www.newscom.com/cgi-bin/prnh/20050207/TNOXLOGO DATASOURCE: Tanox, Inc. CONTACT: Steve Sievert of Tanox, Inc., +1-713-578-4211, or Web site: http://www.tanox.com/

Copyright